CXCL9 and CXCL13 shape endometrial cancer immune‐activated microenvironment via tertiary lymphoid structure formation
Cancer Science · 2025-05 · 116 (5) · 1193-1202
DOI: 10.1111/cas.16371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 17.02.2025. Verfasst von Yoshihiro Nagase und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Tokyo Yamate Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Chemokine CXCL13, Tumor Microenvironment, Chemokine CXCL9, Endometrial Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) therapy has been successfully applied to various cancers; however, not all patients respond to ICI therapy. Tumors with an immune‐activated environment are highly responsive to ICIs. To identify the cells and molecules essential to the formation of an immune‐activated cancer microenvironment, we focused on the tertiary lymphoid structure (TLS) and performed histological and genomic analyses using endometrial cancer material. In the high immunogenic group, numerous TLSs were observed, and CXCL9 and CXCL13 expression was markedly increased. CXCL9‐positive antigen‐presenting and CXCL13‐positive follicular dendritic cells were distributed in the T‐ and B‐cell zones of TLSs, respectively. A group of molecules whose expression was upregulated along with CXCL9 and CXCL13 expression was strongly associated with cellular immunity. These results suggest that CXCL9‐expressing antigen‐presenting cells and CXCL13‐expressing follicular dendritic cells coordinately shape the immune‐activated microenvironment through TLS formation. The current findings will contribute to a better understanding of the mechanisms underlying the activated cancer immune microenvironment, thereby advancing the field of precision cancer medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Tokyo Yamate Medical Center, Tokyo, Japan.
- Department of Human Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
- Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
ORCID-Profile: Makoto Kodama, Kohei Nakamura, Tatsuyuki Chiyoda
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Nagase, Y., Kodama, M., Aimono, E., Nakamura, K., Takamatsu, R., Abe, K., Yoshimura, T., Chiyoda, T., Yamagami, W., & Nishihara, H. (2025). CXCL9 and CXCL13 shape endometrial cancer immune‐activated microenvironment via tertiary lymphoid structure formation. Cancer Science, 116(5), 1193-1202. https://doi.org/10.1111/cas.16371
Vancouver
Nagase Y, Kodama M, Aimono E, Nakamura K, Takamatsu R, Abe K, et al. CXCL9 and CXCL13 shape endometrial cancer immune‐activated microenvironment via tertiary lymphoid structure formation. Cancer Science. 2025;116(5):1193-1202. doi:10.1111/cas.16371
BibTeX
@article{Nagase2025,
author = {Nagase, Yoshihiro and Kodama, Makoto and Aimono, Eriko and Nakamura, Kohei and Takamatsu, Reika and Abe, Keiko and Yoshimura, Takuma and Chiyoda, Tatsuyuki and Yamagami, Wataru and Nishihara, Hiroshi},
title = {CXCL9 and CXCL13 shape endometrial cancer immune‐activated microenvironment via tertiary lymphoid structure formation},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {5},
pages = {1193--1202},
doi = {10.1111/cas.16371}
}
EUVIMED